Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug 14;63(9):789-808.
doi: 10.1016/j.addr.2011.03.008. Epub 2011 Apr 5.

Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery

Challa S S R Kumar  1 , Faruq Mohammad
Affiliations
Review

Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery

Challa S S R Kumar et al. Adv Drug Deliv Rev. .

Abstract

Previous attempts to review the literature on magnetic nanomaterials for hyperthermia-based therapy focused primarily on magnetic fluid hyperthermia (MFH) using mono metallic/metal oxide nanoparticles. The term "hyperthermia" in the literature was also confined only to include use of heat for therapeutic applications. Recently, there have been a number of publications demonstrating magnetic nanoparticle-based hyperthermia to generate local heat resulting in the release of drugs either bound to the magnetic nanoparticle or encapsulated within polymeric matrices. In this review article, we present a case for broadening the meaning of the term "hyperthermia" by including thermotherapy as well as magnetically modulated controlled drug delivery. We provide a classification for controlled drug delivery using hyperthermia: Hyperthermia-based controlled drug delivery through bond breaking (DBB) and hyperthermia-based controlled drug delivery through enhanced permeability (DEP). The review also covers, for the first time, core-shell type magnetic nanomaterials, especially nanoshells prepared using layer-by-layer self-assembly, for the application of hyperthermia-based therapy and controlled drug delivery. The highlight of the review article is to portray potential opportunities for the combination of hyperthermia-based therapy and controlled drug release paradigms--towards successful application in personalized medicine.

PubMed Disclaimer

Figures

Figure-1
Figure-1
A schematic representation of some of the unique advantages of magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery
Figure-2
Figure-2
A schematic representation of possible mechanisms for conversion of magnetic energy into heat (Modified based on figure-13 from Ref 57)
Figure-3
Figure-3
Schematic representation of the two types of controlled drug delivery using magnetic nanoparticle-based hyperthermia.
Figure-4
Figure-4
Size-dependent hyperthermia of MNPs (Reproduced from figure-14 in ref 57).
Figure-5
Figure-5
Demonstration of the concept of DBB in vivo (Reproduced from reference 44).
Figure-6
Figure-6
Stimulus-responsive membrane triggering in vitro (Reproduced from reference 88)
Figure-7
Figure-7
A schematic representation of the principles of ion channel stimulation using nanoparticle heating and local temperature sensing (Reproduced from reference 103).
Figure-8
Figure-8
A schematic representation of “Active drug-elution technology.” (Reproduced from the web site http://www.biophan.com)
Figure-9
Figure-9
Different architectures of nanomaterials.
Figure-10
Figure-10
Solvent dependent SPL values for SPIONs@Au (Reproduced from the reference 131)
Figure-11
Figure-11
Variation in heating rates for FeCo MNPs with change in anisotropy constant (Reproduced from the reference 135).
Figure-12
Figure-12
Scheme of the layer-by-layer sel-assembly and permeability test for microcapsules embedded with Co@Au NPs under an oscillating magnetic field (Reproduced from the reference 19).
Figure 13
Figure 13
A sechematic representation of three different types of nanoconstructs for hyperthermia-based drug delivery type DEP.
See this image and copyright information in PMC

References

    1. Nagarajan S, Yong Z. Use of Core/Shell structured nanoparticles for biomedical applications. Recent Pat. Biomed. Eng. 2008;1:34–42.
    2. http://www.medicinenet.com/hyperthermia/article.html.
    1. Loo GV, Saelens X, Gurp MV, MacFarlane M, Martin SJ, Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 2002;9:1031–1042. - PubMed
    1. Goldstein LS, Dewhirst MW, Repacholi M, Kheifets L. Summary, conclusions and recommendations: adverse temperature levels in the human body. Int. J. Hyperther. 2003;19:373–384. - PubMed
    1. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 2002;43:33–56. - PubMed
    1. Suto R, Srivastava PK. A mechanism for specific immunogenicity of heat shock protein - chaperoned peptides. Science. 1995;269:1585–1588. - PubMed
    2. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. The Lancet Oncol. 2002;3:487–497. - PubMed

Publication types